Director Graham Walmsley resigns from ALX Oncology board effective Aug 26, 2021

ALX ONCOLOGY HOLDINGS INC

Graham Walmsley resigned due to professional responsibilities at Logos Global Management, not due to any disagreement.
Board size reduced from seven to six directors.
Jason Lettmann appointed to the Audit Committee following the resignation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Graham Walmsley

director

ALXO · ALX ONCOLOGY HOLDINGS INC

Effective: 2021-08-26
Filed: August 27, 2021, 7:59 PM ET

On August 26, 2021, Graham Walmsley, M.D., Ph.D., informed the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) that he would resign from the Board effective August 26, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Graham Walmsley resigned as director at ALX ONCOLOGY HOLDINGS INC.

Action: resigned
Role: director

Exact text from the filing

On August 26, 2021, Graham Walmsley, M.D., Ph.D., informed the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) that he would resign from the Board effective August 26, 2021.

View on SEC.gov

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0001564590-21-046136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.